Your browser doesn't support javascript.
loading
Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment.
Jasim, Saade Abdalkareem; Farber, Irina M; Noraldeen, Sara Abdalrazzaq M; Bansal, Pooja; Alsaab, Hashem O; Abdullaev, Bekhzod; Alkhafaji, Adnan Taan; Alawadi, Ahmed Hussien; Hamzah, Hamza Fadhel; Mohammed, Bahira Abdulrazzaq.
  • Jasim SA; Medical Laboratory Techniques Department, Al-Maarif University College, Anbar, Iraq.
  • Farber IM; Department of children's diseases of the F. Filatov clinical institute of children's health, I. M. Sechenov First Moscow State Medical University of Health of Russian Federation (Sechenov University), Moscow, Russia.
  • Noraldeen SAM; Department of Oncology and Metabolism, University of Tabuk, Tabuk, Saudi Arabia.
  • Bansal P; Department of Biotechnology and Genetics, Jain (Deemed-to-be) University, Bengaluru, Karnataka 560069, India; Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan 303012, India.
  • Alsaab HO; Department of Pharmaceutics and Pharmaceutical Technology, Taif University, Taif 21944, Saudi Arabia.
  • Abdullaev B; Research Department of Biotechnology, New Uzbekistan University, Mustaqillik Avenue 54, Tashkent 100007, Uzbekistan; Department of Oncology, School of Medicine, Central Asian University, Milliy Bog Street 264, Tashkent 111221, Uzbekistan.. Electronic address: ayntraxt@gmail.com.
  • Alkhafaji AT; Cardiology Department, College of Medicine, Al-Ayen University, Thi-Qar, Iraq.
  • Alawadi AH; College of Technical Engineering, the Islamic University, Najaf, Iraq; College of Technical Engineering, the Islamic University of Al Diwaniyah, Qadisiyyah, Iraq; College of Technical Engineering, the Islamic University of Babylon, Babylon, Iraq.
  • Hamzah HF; Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq.
  • Mohammed BA; Department of Technical Engineering, Al-Hadi University College, Baghdad 10011, Iraq.
Microvasc Res ; 154: 104691, 2024 07.
Article en En | MEDLINE | ID: mdl-38703993
ABSTRACT
Neoadjuvant targeting of tumor angiogenesis has been developed and approved for the treatment of malignant tumors. However, vascular disruption leads to tumor hypoxia, which exacerbates the treatment process and causes drug resistance. In addition, successful delivery of therapeutic agents and efficacy of radiotherapy require normal vascular networks and sufficient oxygen, which complete tumor vasculopathy hinders their efficacy. In view of this controversy, an optimal dose of FDA-approved anti-angiogenic agents and combination with other therapies, such as immunotherapy and the use of nanocarrier-mediated targeted therapy, could improve therapeutic regimens, reduce the need for administration of high doses of chemotherapeutic agents and subsequently reduce side effects. Here, we review the mechanism of anti-angiogenic agents, highlight the challenges of existing therapies, and present how the combination of immunotherapies and nanomedicine could improve angiogenesis-based tumor treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Inmunoterapia / Neoplasias / Neovascularización Patológica Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Inmunoterapia / Neoplasias / Neovascularización Patológica Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article